Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Endometrial Neoplasms 1

Interventions

olaparib 6Specimen Handling 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 4Carboplatin 4pembrolizumab 3fludarabine 3X-Rays 3Taxes 3Metformin 3Letrozole 3Fluorodeoxyglucose F18 3Biopsy 3Aspirin 3niraparib 2Tirzepatide 2Radiotherapy 2Propranolol 2Platinum 2Pafolacianine 2Oncolytic Virotherapy 2Hysterectomy 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorescein 2Drug Therapy 2Doxorubicin 2Cytoreduction Surgical Procedures 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Dasatinib × Gynecologic × Clear all
NCT01482728 2016-05-13

Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer

University of Virginia

Phase EARLY_PHASE1 Completed
12 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡